First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Francisco J. Moreno(Instituto de Química Médica), Ana Castro(Instituto de Química Médica), Mercedes Alonso(Instituto de Química Médica), Concepción Pérez(Instituto de Química Médica)
Cited by 448
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293
Targeting autophagy in disease: established and new strategies
|Autophagy|2021|229